Inspire Medical Systems (NYSE:INSP) Rating Lowered to Hold at Zacks Research

Inspire Medical Systems (NYSE:INSP) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks reports.

Several other brokerages have also issued reports on INSP. Mizuho increased their price target on Inspire Medical Systems from $55.00 to $65.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Truist Financial restated a “hold” rating and set a $62.00 price objective (up from $54.00) on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Weiss Ratings raised Inspire Medical Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday. KeyCorp reiterated a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Finally, Piper Sandler boosted their price target on shares of Inspire Medical Systems from $55.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $66.50.

Inspire Medical Systems Trading Down 3.1%

INSP opened at $69.07 on Tuesday. The company has a fifty day moving average price of $60.79 and a two-hundred day moving average price of $53.18. Inspire Medical Systems has a 1-year low of $38.91 and a 1-year high of $147.03. The company has a market cap of $2.00 billion, a P/E ratio of 14.95, a price-to-earnings-growth ratio of 5.39 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. The company had revenue of $200.58 million for the quarter, compared to analysts’ expectations of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business’s revenue was down 7.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, research analysts forecast that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Jason Kelly sold 963 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider directly owned 18,985 shares of the company’s stock, valued at $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Envestnet Portfolio Solutions Inc. bought a new stake in Inspire Medical Systems during the second quarter worth $296,000. WINTON GROUP Ltd lifted its stake in Inspire Medical Systems by 790.8% during the 2nd quarter. WINTON GROUP Ltd now owns 37,412 shares of the company’s stock valued at $1,669,000 after acquiring an additional 33,212 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Inspire Medical Systems during the 2nd quarter worth $131,000. Allworth Financial LP boosted its holdings in Inspire Medical Systems by 275.7% during the 2nd quarter. Allworth Financial LP now owns 1,980 shares of the company’s stock worth $88,000 after acquiring an additional 1,453 shares during the last quarter. Finally, Nykredit A S bought a new stake in shares of Inspire Medical Systems in the 2nd quarter worth $78,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for treating moderate to severe obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed for patients who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses a small implantable pulse generator, a breathing-sensing lead and a stimulation lead.